MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
12.79
-0.61
-4.55%
After Hours: 12.79 0 0.00% 18:56 04/10 EDT
OPEN
13.43
PREV CLOSE
13.40
HIGH
13.60
LOW
12.36
VOLUME
3.31M
TURNOVER
--
52 WEEK HIGH
20.76
52 WEEK LOW
6.71
MARKET CAP
1.97B
P/E (TTM)
-32.6109
1D
5D
1M
3M
1Y
5Y
1D
Adaptive Biotechnologies Chief People Officer Francis Lo sells $340,043 common shares
Reuters · 1d ago
Adaptive Biotech CSO Harlan Robins sells 10,000 shares worth $148,500
Reuters · 1d ago
Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings
Seeking Alpha · 1d ago
Adaptive Biotechnologies CEO Chad Robins disposes of USD 1.8 million common shares
Reuters · 3d ago
Adaptive Biotechnologies President, COO Julie Rubinstein disposes of USD 983,470 shares
Reuters · 3d ago
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
The Motley Fool · 4d ago
Adaptive Biotechnologies (ADPT) Is Up 15.3% After Beating Q4 Views And Striking Pfizer Deals
Simply Wall St · 6d ago
Weekly Report: what happened at ADPT last week (0330-0403)?
Weekly Report · 6d ago
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.